

The unintended consequences of the Inflation Reduction Act threaten patient health and America's leadership in the life sciences. As policymakers continue to evaluate the law's implementation, it is important to consider the real-world impact this law is having on patient access, innovation, and American jobs.

Protecting America's leadership in life sciences innovation is essential, and today that must start with understanding the current policy environment, threats, and opportunities.

Read what industry experts have to say about IRA's current impact.

“

APRIL 26, 2024

**Rob Michael, President and Chief Operating Officer
AbbVie**

“When you think about that [Medicare Part D] redesign impact, it will really spread across our business, most concentrated in immunology and oncology.”

[**AbbVie \(ABBV\) Q1 2024 Earnings Call Transcript**](#)

“

APRIL 16, 2024

**Jennifer Taubert, Executive Vice President, Worldwide Chairman,
Innovative Medicine
Johnson & Johnson**

“We've been really clear that we do think the IRA drug setting provisions are damaging to the healthcare innovative system. It is not something that is going to help reinforce the tremendous investments that we're making in R&D to develop the next types of treatments and cures.”

[**Johnson & Johnson \(JNJ\) Q1 2024 Earnings Call Transcript**](#)

Read what industry experts have to say about IRA's current impact:



MARCH 4, 2024

Suneet Varma, Commercial President Pfizer Oncology

"Biologics have that 13-year versus the 9-year [for small molecules] before you enter negotiation or price negotiations, so I think that all of that strengthens the case and that has driven us to be deliberate intentionally not just on our tumor types but on the modalities that you heard about today—the ADCs as well as the bispecifics."

IRA Drive Pfizer's Decision to Focus on Biologics, Not Small Molecules



JANUARY 17, 2024

Peter Kolchinsky, Co-Founder RA Capital Management

"It would be as if a company came to us and said, "Hey, will you fund my preclinical project? Oh, and by the way, when we launch, we will only have nine years of patent exclusivity left.' Of course, I know that for years, if we ever looked at a project and knew we would have only nine years on the market before going generic, we would say, 'Oh, that's too short. So I already know what my decision is."

Vital Health Podcast: "IRA's 9 Years Is Too Short"



SEPTEMBER 27, 2023

Steve Potts, Founding CEO AZBio

"I surveyed 100 VCs and biotech executives and [asked] two questions: Are you seeing a decline in small molecule funding for the elderly? Are you planning a decline based on this IRA? 85% of them are pulling out of small molecule research for the elderly as a result."

Vital Health Podcast: "Cancer Drug Developer Dr. Steve Potts' Congressional Testimony on the IRA"

Read what industry experts have to say about IRA's current impact:



AUGUST 29, 2023

Giovanni Caforio, Chairman and CEO Bristol Myers Squibb

"It makes no sense to take a medicine that is already priced based on the value it delivers and demand even greater concessions, especially given that there is no requirement that the insurance companies that administer Medicare benefits will pass any new savings to patients."

[The High Cost of Price Controls on Eliquis and Other Drugs](#)



JULY 27, 2023

Thomas Schinecker, CEO Roche

"We have decided that we are not going to do certain trials, or that we are not going to do a merger or acquisition or licensing [deal] because it is becoming financially not viable."

[Roche: Have Abandoned Some Trials Due to U.S. Drug Pricing Plans](#)



JULY 6, 2023

Alexander Hardy, CEO Genentech

"These are not the sorts of dilemmas we like to have to make. We'd like to put the patient first. But now we're trying to figure out how to make a return with a nine-year clock."

[Genentech CEO Hardy warns of 'unintended consequences' from the Inflation Reduction Act](#)

Read what industry experts have to say about IRA's current impact:

“

JUNE 21, 2023

Barry Greene, CEO Sage Therapeutics

“Those decisions [bypassing Medicare] may have dire consequences on the elderly. Companies should not be forced to choose patient winners and losers, an unfortunate consequence of the IRA.”

[Biopharma Execs Weigh Controversial Move: Option Out of Medicare to Escape Drug Price Negotiations](#)

“

JUNE 14, 2023

David Ricks, CEO Eli Lilly

“So you raise the question of should I even try for government access for new innovation if it's going to get caught up in potential downstream negotiation.”

[IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says](#)

“

MAY 19, 2023

Vas Narasimhan, CEO Novartis

“The company has cut some early-stage cancer drug programs because ‘nine years is just too short a time period to fully develop a drug across all of the indications ... and make a reasonable return.’”

[Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations](#)

Read what industry experts have to say about IRA's current impact:

“

OCTOBER 27, 2022

Yvonne Greenstreet, EO Alnylam

Alnylam announced it's reconsidering developing RNA interference therapy for Stargardt disease, a rare genetic eye disease that can cause vision loss because of the IRA and potential price negotiations. The company wanted to pause the Stargardt disease plans to "consider the options for the best path forward."

[As Amvuttra makes inroads in ATTR, Alnylam scraps heart disease trial interim analysis, rethinks another rare disorder plan](#)